This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Sheehan syndrome / Postpartum hypopituitarism쉬한증후군 (산후 뇌하수체 괴사)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E23.0 (Sheehan syndrome) | Special Copayment Reduction: V165 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsPostpartum hypopituitarism, Postpartum pituitary necrosis, Simmonds' disease, Postpartum pituitary infarction
C. Adult onsetVery high likelihood of first presenting in adulthood — a disease triggered by postpartum hemorrhage and hypotension that occurs only in women of reproductive age, and diagnosis is often delayed by months to decades.
1. History1937: Harold Sheehan first systematically describes postpartum pituitary necrosis → proposes that massive hemorrhage and hypotension during delivery cause ischemic necrosis of the pituitary → subsequently established as the representative acquired cause of panhypopituitarism.
2. CausesIschemic necrosis of the anterior pituitary due to massive hemorrhage and hypotension during delivery. Pituitary enlargement during pregnancy (especially lactotroph hyperplasia) increases vascular vulnerability. Autoimmune mechanisms may coexist.
3. GeneticsMainly a non-hereditary acquired disease, but anti-pituitary antibody positivity and autoimmune predisposition have been reported in some cases. Studies exist on associations with specific HLA subtypes.
4. General epidemiologyIncidence has decreased in high-income countries (improved obstetric care). A leading cause of panhypopituitarism in developing countries. Accurate prevalence statistics in Korea are lacking. Worldwide incidence is approximately 5/100,000 deliveries.
5. PathophysiologyIncreased pituitary volume during pregnancy (about 136%) → greater vulnerability of pituitary portal blood flow → hypotension and hemorrhage at delivery → ischemic necrosis of the anterior pituitary → multiple hormone deficiencies.
6. SymptomsPanhypopituitarism symptoms including inability to lactate (early clue), amenorrhea, fatigue and lethargy, hypothermia, weight gain, hair loss, dry skin, and decreased libido; Addisonian crisis in severe cases.
7. SignsLoss of axillary and pubic hair, pale and dry skin, hypotension, hypoglycemia, hyponatremia, bradycardia, empty sella on pituitary MRI.
8. ScreeningSuspect in women with postpartum inability to lactate and persistent amenorrhea. Basic measurements: serum FSH/LH, prolactin, FT4/TSH, cortisol (8 a.m.), IGF-1.
9. DiagnosisConfirmation of multiple pituitary hormone deficiencies + insulin tolerance test (ITT) or metyrapone test + pituitary MRI (empty sella). A history of massive hemorrhage at delivery is key.
10. TreatmentLifelong replacement of deficient hormones: hydrocortisone (top priority), levothyroxine, estrogen-progestin, GH (if needed). Education on emergency hydrocortisone in preparation for adrenal crisis is essential.
11. PrognosisNormal life is possible with appropriate hormone replacement. Mortality increases with delayed diagnosis (adrenal crisis). Spontaneous recovery of pituitary function is rare but has been reported. Accompanied by reduced quality of life.
12. PreventionPrompt management of obstetric hemorrhage (transfusion, uterotonics, surgical hemostasis) reduces the risk of occurrence. Perform early endocrine evaluation in women with postpartum inability to lactate.
13. ReferencesSheehan HL. Postpartum necrosis of the anterior pituitary. J Pathol Bacteriol. 1937 … and 9 other papers

1. History

The history of Sheehan syndrome begins at the intersection of obstetrics and endocrinology in the early 20th century. In 1914, the German pathologist Morris Simmonds first reported necrosis of the anterior pituitary at the autopsy of a woman who died of puerperal fever and linked it to loss of pituitary function. At the time, it was understood as a localized lesion caused by pituitary infection or sepsis, and the accompanying panhypopituitarism was called 'Simmonds' disease'. However, Simmonds' description lacked a systematic explanation of the causal mechanism, and the direct relationship between pituitary necrosis and hemorrhage during delivery had not yet been established.

The decisive turning point was provided by the British pathologist Harold Leeming Sheehan (1900–1988). In 1937, Sheehan systematically analyzed autopsy specimens of the pituitary from female patients who died after childbirth in Manchester and published a paper titled “Postpartum necrosis of the anterior pituitary” in the Journal of Pathology and Bacteriology. In this paper he was the first to clearly demonstrate that anterior pituitary necrosis is closely associated with severe hemorrhage during delivery and the resulting drop in blood pressure. In particular, he demonstrated pathologically that in late pregnancy the pituitary enlarges to about 136% or more of normal while its blood supply remains relatively limited, making it extremely vulnerable to ischemic injury in a hypotensive state.

Over the following decades, Sheehan refined his observations and clinically traced inability to lactate, amenorrhea, chronic fatigue, and hypothyroidism and hypoadrenalism after childbirth as direct consequences of pituitary necrosis. In 1948, together with his colleague Murdoch, he published a paper systematizing the clinical features of puerperal pituitary insufficiency, establishing the clinical-medical reality of this disease. Because of this achievement, the name 'Sheehan syndrome' was given to postpartum hypopituitarism, which partly replaced the comprehensive diagnostic name derived from Simmonds.

In the second half of the 20th century, with improvements in obstetric management, particularly the development of transfusion technology and the ability to respond promptly to obstetric hemorrhage at delivery, the incidence of Sheehan syndrome fell markedly in high-income countries. However, it remains one of the most common causes of panhypopituitarism in developing countries and regions with weak medical infrastructure. In the 1990s and 2000s, with the spread of pituitary MRI, the 'empty sella' finding became established as an imaging diagnostic indicator of Sheehan syndrome, and with the pathophysiological similarity to autoimmune hypophysitis pointed out, research on the role of autoimmune mechanisms also became active. Now, with growing recognition of the chronic form diagnosed decades after delivery, a clinical consensus has formed that Sheehan syndrome should be actively differentiated in female patients complaining of postpartum amenorrhea or inability to lactate.


2. Causes

The fundamental cause of Sheehan syndrome is ischemic necrosis of the anterior pituitary occurring in the peripartum period. This necrosis is caused by massive hemorrhage during or immediately after delivery and the resulting severe hypotension, which abruptly reduce blood flow in the pituitary portal system. During pregnancy, the pituitary enlarges up to 136% of normal volume owing to marked proliferation of prolactin-secreting cells (lactotrophs), and as a result the dural sinuses and pituitary portal vessels surrounding the pituitary are compressed, leaving the blood supply relatively fragile. When hypotension accompanies delivery in this setting, selective ischemia occurs in the enlarged anterior pituitary, particularly the central zone, where vascular distribution is relatively sparse, leading to extensive necrosis.

The blood supply to the pituitary comes from two main routes. Portal vessels originating from the superior hypophyseal artery supply oxygen and nutrients to the anterior pituitary, while the inferior hypophyseal artery mainly supplies the posterior lobe. There is no rich anastomosis between these two arterial systems, so when the perfusion pressure of the superior hypophyseal artery falls, the anterior lobe is exposed to severe risk of ischemia. It is thought that when bleeding of 2 liters or more or hypotension with systolic blood pressure below 80 mmHg persists for a considerable time during delivery, thrombus formation or vasospasm occurs in this vulnerable portal system and aggravates ischemic injury.

Recent studies provide evidence supporting that, in addition to the purely ischemic mechanism, an autoimmune mechanism may contribute to the pathophysiology. Anti-pituitary antibodies are detected in some patients with Sheehan syndrome, which is interpreted as a secondary autoimmune response to pituitary antigens exposed by ischemic injury. It has been hypothesized that this autoimmune response may continue to worsen pituitary function impairment even after the initial ischemic injury, or may be the main etiology in Sheehan syndrome-like cases without a clinically clear history of hemorrhage. In addition, associations between specific HLA genotypes (e.g., HLA-B8, HLA-DR3) and anti-pituitary antibody positivity have been reported, so a subgroup in which autoimmune predisposition contributes to onset may exist.

As risk factors, obstetric complications that cause hemorrhage are the most important, including heavy bleeding during delivery (postpartum hemorrhage, PPH, 500 mL or more), placental abruption, placenta previa, and uterine atony. Twin pregnancy and preeclampsia are also known to be factors that raise the risk. On the other hand, in advanced obstetric systems that actively manage delivery complications with high mortality, severe hypotension during delivery is uncommon and the incidence has decreased greatly. However, in settings with limited access to medical care, postpartum hemorrhage is still not adequately managed and leads to pituitary ischemia.


3. Genetics

Sheehan syndrome is typically classified as an acquired non-hereditary disease. The core mechanism of the disease is anterior pituitary necrosis from a physical ischemic event during delivery, and it does not follow a Mendelian inheritance pattern. Therefore, it is not directly inherited from parents to children, and familial clustering is also generally not seen.

However, a small number of studies have provided evidence that a specific immunogenetic background may influence susceptibility to Sheehan syndrome. The most notable area is the association between anti-pituitary antibodies (APA) and HLA genes. In some Sheehan syndrome patient cohorts, the APA positivity rate was significantly higher than in controls, and APA-positive patients tended to show more severe hypopituitarism and more axes of damage. This autoimmune predisposition is also partly confirmed in association with autoimmune thyroid disease or type 1 diabetes.

In HLA association studies, there are small-scale study results showing that HLA subtypes commonly associated with autoimmune diseases, such as HLA-B8, HLA-DR3, and HLA-DQ2, are observed at a higher frequency in patients with Sheehan syndrome. These HLA types are more common in individuals with weakened immune tolerance, which eliminates autoreactive T cells, and may promote an autoimmune response to pituitary antigens exposed by ischemia. However, this genetic association is still based on small studies and is not clinically used as an established genetic risk factor.

Other hereditary causes of hypopituitarism include variants in pituitary transcription factor genes such as PROP1, POU1F1, HESX1, LHX3, and LHX4, but these are causes of congenital hypopituitarism distinct from Sheehan syndrome and are characterized by onset in childhood without a history of postpartum hemorrhage. When diagnosing Sheehan syndrome, differentiation from these congenital forms is necessary, and genetic testing should be considered particularly when the delivery history is unclear or the degree of hemorrhage is mild. Overall, it should be emphasized that although genetic vulnerability may be partly involved in Sheehan syndrome, the main determinants of onset are obstetric risk factors (the degree of hemorrhage and the duration of hypotension).


4. General epidemiology

The incidence of Sheehan syndrome differs markedly by region and medical setting. In Western high-income countries, the incidence has decreased markedly owing to improved obstetric care, namely prompt transfusion for hemorrhage during delivery, use of uterotonics, and aggressive surgical intervention. In the West, the proportion of hypopituitarism caused by Sheehan syndrome has decreased greatly compared with the past, and pituitary tumors, craniopharyngioma, and cranial irradiation are now reported as more common causes.

In contrast, it remains one of the main causes of panhypopituitarism in developing countries. Epidemiological studies conducted in India, Egypt, Turkey, Pakistan, and elsewhere reported that Sheehan syndrome accounts for 30–60% of hypopituitarism in women of childbearing age. In an Egyptian cohort study conducted by Sherif et al. (2019), long-term pituitary function impairment was identified in about 5% of women who had postpartum hemorrhage. The worldwide incidence is estimated at roughly 5/100,000 deliveries, but regional variation is large.

In Korea, the occurrence of Sheehan syndrome has become rare owing to improvements in childbirth culture and the standard of obstetric care, but according to rare disease registration data, a small number of new patients are registered each year. The prevalence can be indirectly estimated from the number of patients registered under the Special Copayment Reduction code V165 in data from the Korean Endocrine Society and the Health Insurance Review & Assessment Service (HIRA), but no large-scale published epidemiological study exists yet. Diagnosis is often delayed by months to decades, so the actual prevalence may be higher than official statistics.

As risk factors, the amount of bleeding during delivery, the duration of hypotension, delay in transfusion, and limited access to medical care are the most important. The risk is known to increase significantly when bleeding of 1,000 mL or more occurs during delivery, and the risk of pituitary ischemic injury is known to be markedly higher when systolic blood pressure remains below 80 mmHg for 30 minutes or more. By age, no particular age group is conspicuously vulnerable, but the risk may be somewhat higher in older pregnant women because of increased vascular fragility. It is also pointed out that in women with multiparity, exposure risk may accumulate through multiple deliveries.


5. Pathophysiology

The pathophysiology of Sheehan syndrome is understood as a combination of physiological changes in the pituitary during pregnancy and hemodynamic injury at delivery. The anterior pituitary of a normal non-pregnant woman weighs about 0.5–0.6 g and lies within the sella turcica. During pregnancy, under strong estrogen stimulation, prolactin-secreting cells proliferate markedly, and the volume of the anterior pituitary increases by up to 136% or more. In this enlarged pituitary, the portal vessels are further dilated and fragile in order to accommodate the blood flow coming from the surrounding dural sinuses (cavernous sinus, diaphragma sellae).

The blood supply to the anterior pituitary is mainly through the hypophyseal portal system originating from the superior hypophyseal artery. This portal system has a unique structure that delivers both oxygen and hypothalamic releasing hormones to the anterior pituitary. Anatomically, however, the central zone of the anterior pituitary has a lower vascular density than the periphery and is therefore the first to become vulnerable to ischemic injury when blood flow decreases. When massive hemorrhage occurs at delivery and systemic blood pressure falls abruptly, blood flow in this vulnerable central zone drops below the critical level and ischemic necrosis begins.

At the cellular level, ischemia-induced ATP depletion, intracellular calcium overload, and increased generation of reactive oxygen species (ROS) drive cell death (necrosis). In severe cases, DIC (disseminated intravascular coagulation) accompanies it, microthrombi form in the pituitary portal system, and the extent of ischemia expands. The necrotic pituitary tissue is resorbed and fibrosed over time, and ultimately an empty sella finding, in which the sella turcica appears empty, appears on MRI.

The degree of ischemic injury is proportional to the severity of the associated hormone deficiencies. It is known that clinically significant hormone deficiency manifests when 75% or more of the anterior pituitary parenchymal cells are damaged. Depending on the extent of damage, the GH axis, gonadotropin axis, thyrotropin axis, and ACTH axis may be damaged sequentially or simultaneously, and because ischemia occurs when prolactin-secreting cells are most extensively proliferated, inability to lactate becomes the earliest clinical clue. When an autoimmune mechanism coexists, continued injury by anti-pituitary antibodies may progress even after ischemic necrosis, and hypofunction may worsen gradually.


6. Symptoms

The symptoms of Sheehan syndrome vary widely depending on the type and extent of damaged anterior pituitary cells and can be divided into acute and chronic phases. The earliest clinical clue is failure of lactation after delivery. After a normal delivery, estrogen and progestin levels fall sharply, the milk-secretion-promoting action of prolactin is activated, and milk production begins. However, when prolactin-secreting cells are extensively destroyed by Sheehan syndrome, serum prolactin levels are very low and lactation does not occur. Sheehan syndrome must be differentiated in women in whom no milk comes out at all even when breastfeeding is attempted after delivery.

Persistent amenorrhea within 6 weeks to 6 months after delivery, or absence of the first postpartum menstruation, is also an important symptom. This reflects secondary hypogonadism due to gonadotropin (FSH, LH) deficiency. Along with this, sexual dysfunction such as decreased libido, vaginal dryness, and dyspareunia may also occur.

Thyroid-stimulating hormone (TSH) deficiency causes secondary hypothyroidism, producing symptoms such as fatigue, lethargy, cold intolerance, weight gain, constipation, dry skin, bradycardia, and hair loss. Secondary adrenal insufficiency due to ACTH deficiency is the most life-threatening problem; chronically it presents with fatigue, decreased appetite, hypotension, hyponatremia, and hypoglycemia, and acute adrenal crisis (Addisonian crisis) can occur in stressful situations. Growth hormone (GH) deficiency manifests in adults as increased body fat, decreased muscle mass, reduced vitality, and reduced quality of life.

In chronic Sheehan syndrome, these symptoms progress gradually over months to decades, and patients themselves often mistake them for gradual weakness or part of aging. As a result, diagnosis may be delayed by more than 10 years on average. Pale skin, generalized weakness, and loss of axillary and pubic hair are characteristic findings of the chronic phase, and with long-term neglect, serious cardiovascular complications, osteoporosis, and cognitive decline may accompany it.


7. Signs

The physical signs of Sheehan syndrome vary according to the combination of deficient hormone axes. The most characteristic external finding is marked reduction or loss of axillary and pubic hair, which reflects androgen deficiency due to gonadal hypofunction. The skin may appear pale and dry with increased wrinkling. Loss of the lateral one-third of the eyebrows (similar to deficiency hypothyroidism) is also observed.

Regarding vital signs, hypotension (especially orthostatic hypotension) and bradycardia are common, resulting from the combination of hypothyroidism and adrenal hypofunction. During a hypoglycemic attack, cold sweats, decreased consciousness, and seizures may occur. On examination, decreased muscle strength and delayed deep tendon reflexes may also be found.

On laboratory findings, hyponatremia is the most common electrolyte abnormality; decreased cortisol due to ACTH deficiency causes excess secretion of antidiuretic hormone (ADH), producing dilutional hyponatremia. Blood cortisol, FT4, FSH, LH, and IGF-1 levels are all low, and TSH is low or inappropriately low within the normal range in secondary hypothyroidism. Decreased hemoglobin (normocytic anemia), low blood glucose, and elevated blood cholesterol and LDL may accompany these.

As an imaging finding, empty sella on pituitary MRI (including contrast enhancement) is the most typical. This is a state in which the necrotic pituitary tissue has been resorbed and the sella turcica is filled with cerebrospinal fluid, appearing on T1-weighted images as if the sella is filled with homogeneous low-signal-intensity fluid. In some acute or subacute cases, early on the infarcted area of the anterior pituitary may be enhanced, or high signal intensity reflecting hemorrhage may be observed. Bone density testing commonly shows osteoporosis findings due to long-term sex hormone deficiency.


8. Screening

Screening for Sheehan syndrome is based mainly on clinical suspicion. Evaluation should be actively started in women who have one or more of the following situations after delivery: ① bleeding of 500 mL or more or a severe hypotensive episode during delivery, ② no breast milk at all or failure to lactate after delivery, ③ amenorrhea persisting for 6 weeks or more after delivery, ④ unexplained fatigue and lethargy persisting after delivery.

For initial screening, measurement of baseline serum hormones is recommended. Specifically, measure simultaneously 8 a.m. serum cortisol (free cortisol or total cortisol), serum FT4 and TSH, serum FSH, LH, and estradiol, serum IGF-1 (indirect assessment of the growth hormone axis), and serum prolactin. Electrolyte tests (sodium, potassium) and fasting blood glucose are also performed as a basic workup. If 8 a.m. serum cortisol is 18 μg/dL or higher, adrenal function can generally be judged normal, but in the 3–18 μg/dL range, additional stimulation testing is needed.

For imaging, pituitary MRI (gadolinium contrast-enhanced) is recommended early in the screening workup. The empty sella finding is not specific to Sheehan syndrome, but when observed together with findings of hypopituitarism in a patient with a history of postpartum hemorrhage, it is strong supporting evidence. It is also essential for excluding pituitary tumors, craniopharyngioma, lymphocytic hypophysitis, and the like.

When long-term follow-up is needed, it is reasonable to repeat pituitary function evaluation at 6 weeks, 6 months, and 1 year in all women who had severe postpartum hemorrhage. Even if results are initially within the normal range, delayed damage by autoimmune mechanisms may progress, so reevaluation is essential if clinical symptoms persist or newly develop.


9. Diagnosis

Definitive diagnosis of Sheehan syndrome is made by the combination of three elements: ① a history of massive hemorrhage or severe hypotension during delivery, ② biochemical demonstration of multiple anterior pituitary hormone deficiencies, and ③ empty sella or pituitary atrophy on pituitary MRI. If any one of these is lacking, differential diagnosis must be performed thoroughly.

The insulin tolerance test (ITT) is performed as the standard dynamic test for evaluating adrenal function. After lowering blood glucose to 40 mg/dL or below by intravenous insulin, if serum cortisol does not rise to 18 μg/dL or higher, insufficiency of the ACTH-cortisol axis is determined. When the ITT is contraindicated (epilepsy, coronary artery disease, advanced age), it can be replaced by the metyrapone test or the low-dose cosyntropin stimulation test. Growth hormone deficiency is evaluated by measuring the GH response during the ITT, in addition to low serum IGF-1.

Thyroid function is evaluated by measuring serum FT4 and TSH simultaneously to differentiate secondary hypothyroidism (low FT4 + normal or inappropriately low TSH) from primary hypothyroidism (low FT4 + elevated TSH). Gonadal function is evaluated by measuring serum FSH, LH, and estradiol; in premenopausal women, secondary hypogonadism is diagnosed when both FSH and LH are low and estradiol is decreased. Anti-pituitary antibody testing is performed when an autoimmune mechanism is suspected and is used as a diagnostic adjunct.

Major diseases to be differentiated from Sheehan syndrome include lymphocytic hypophysitis, pituitary tumors (especially craniopharyngioma), hypopituitarism after head trauma, pituitary involvement by sarcoidosis and other granulomatous diseases, and congenital hypopituitarism. Lymphocytic hypophysitis occurring within several months after delivery has a clinical picture very similar to Sheehan syndrome, so MRI findings (pituitary enlargement and stalk thickening) and history taking are important differentiating tools.


10. Treatment

Treatment of Sheehan syndrome is founded on lifelong replacement therapy of the deficient pituitary hormones or target organ hormones. Treatment priority starts with life-threatening hormone deficiencies, proceeding in the order of cortisol → thyroid hormone → sex hormones → growth hormone.

Treatment of adrenocortical insufficiency is the highest priority. Because giving thyroid hormone before evaluating and replacing adrenal function can precipitate adrenal crisis, hydrocortisone must be given first, and thyroid hormone added afterward. The standard hydrocortisone regimen is 15–25 mg per day orally in divided doses (e.g., 10–15 mg in the morning, 5–10 mg in the evening). Patient education is essential to increase the dose 2- to 3-fold in stressful situations such as surgery, high fever, and vomiting (sick day rules), and prescribing emergency hydrocortisone injection (100 mg intramuscular) is recommended in case of loss of consciousness.

Treatment of hypothyroidism replaces secondary hypothyroidism with levothyroxine. Because it is secondary, the TSH level cannot be used as a treatment target indicator; the goal is to keep serum FT4 at the midpoint of the normal range. The initial dose starts at 25–50 μg/day and is adjusted at intervals of 4–6 weeks.

Treatment of hypogonadism in premenopausal women uses combined estrogen-progestin therapy to restore physiological cycles and reduce osteoporosis and cardiovascular risk. When pregnancy is desired, ovulation induction is possible with gonadotropin (FSH/LH) injections or a gonadotropin-releasing hormone (GnRH) pump, and normal pregnancies in patients with Sheehan syndrome have in fact been reported.

Treatment of growth hormone deficiency uses subcutaneous injection of recombinant human growth hormone (rhGH) in adults to improve body fat distribution, muscle mass, quality of life, bone density, and cardiovascular risk indicators. National Health Insurance coverage in Korea applies when the diagnostic criteria for adult GH deficiency are met. All patients on hormone replacement should be educated to carry a hormone replacement card at all times, along with regular biochemical monitoring (hormone levels, electrolytes, blood glucose, lipids, bone density).


11. Prognosis

The prognosis of Sheehan syndrome is relatively good when appropriate hormone replacement therapy is given. Patients who receive adequate replacement of all deficient hormones can lead normal social activities and lives, and pregnancy is also possible. However, the later the diagnosis, the worse the prognosis; in particular, when stress such as surgery, infection, or trauma is applied in the state of unrecognized adrenal insufficiency, life-threatening adrenal crisis can occur.

Several important complications are reported in relation to long-term prognosis. First, osteoporosis due to long-term sex hormone deficiency increases the risk of vertebral compression fractures and hip fractures. Appropriate estrogen replacement and vitamin D and calcium supplementation are important in preventing this. Second, if growth hormone deficiency persists, cardiovascular risk increases, with progression of abdominal obesity, dyslipidemia, and endothelial dysfunction. Third, quality of life may decline markedly due to chronic fatigue and cognitive decline, which is partly improved by GH replacement.

Spontaneous recovery of pituitary function is very rare but not completely excluded. In some cases, partial recovery of a particular hormone axis (mainly the gonadotropin axis) within months to years after delivery has been reported, which may be related to immune stabilization by treatment when an autoimmune mechanism coexists. However, functional recovery is hard to expect when extensive ischemic necrosis has occurred. The life expectancy of patients who start hormone replacement early after diagnosis and are appropriately monitored is known not to differ greatly from that of the general population, but when diagnosis is delayed or treatment is not received, the risk of death from cardiovascular disease and infection increases.


12. Prevention

Primary prevention of Sheehan syndrome depends mainly on prevention and early management of obstetric hemorrhage. Postpartum hemorrhage (PPH) is one of the leading causes of maternal death worldwide, and active management of the third stage of labor (AMTSL) has been shown to be effective in reducing the incidence of PPH. Specifically, prophylactic administration of uterotonics (oxytocin, misoprostol), continuous uterine massage, and induction of early delivery of the placenta are included in standard management. When hemorrhage occurs, the key is to minimize the duration of hypotension through prompt transfusion, additional uterotonics, and, if necessary, uterine compression sutures or hysterectomy.

Identifying high-risk groups before delivery is also important. Mothers with placenta previa, placenta accreta spectrum disorder, coagulation disorders, or a history of previous uterine surgery should be planned to deliver at a high-risk medical institution. Correcting antenatal anemia (iron supplementation, and transfusion in some cases) also helps secure a reserve against bleeding at delivery.

For secondary prevention (early detection and early diagnosis), it is recommended that all women who experienced postpartum hemorrhage have an endocrine evaluation included at the 6-week and 6-month postpartum follow-up visits. If symptoms such as inability to lactate, postpartum amenorrhea, or persistent fatigue are present, refer immediately to endocrinology. In addition, chronic Sheehan syndrome diagnosed late should be considered in middle-aged women with a previous history of massive hemorrhage who now have amenorrhea, fatigue, and skin changes. Early diagnosis and start of treatment play a decisive role in preventing adrenal crisis and reducing osteoporosis and cardiovascular complications.


13. References

  1. Sheehan HL. Postpartum necrosis of the anterior pituitary. J Pathol Bacteriol. 1937;45(1):189–214. doi:10.1002/path.1700450118
  2. Sheehan HL, Murdoch R. Postpartum necrosis of the anterior pituitary: pathological and clinical aspects. J Obstet Gynaecol Br Emp. 1938;45(3):456–488. doi:10.1111/j.1471-0528.1938.tb07178.x
  3. Kelestimur F. Sheehan's syndrome. Pituitary. 2003;6(4):181–188. doi:10.1023/B:PITU.0000023425.78243.19 PMID: 15237929
  4. Gei-Guardia O, Soto-Herrera E, Gei-Brealey A, Chen-Ku CH. Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract. 2011;17(3):361–368. doi:10.4158/EP10200.OR PMID: 21041173
  5. Diri H, Tanriverdi F, Karaca Z, et al. Extensive investigation of 114 patients with Sheehan's syndrome: a continuing disorder. Eur J Endocrinol. 2014;171(3):311–318. doi:10.1530/EJE-14-0244 PMID: 24920291
  6. Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F. Sheehan syndrome. Nat Rev Dis Primers. 2016;2:16092. doi:10.1038/nrdp.2016.92 PMID: 27905467
  7. Tanriverdi F, Silveira LF, MacColl GS, Bhagavath B. The hypothalamic–pituitary–gonadal axis: immune function and autoimmunity. J Endocrinol. 2003;176(3):293–304. doi:10.1677/joe.0.1760293 PMID: 12630914
  8. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999;50(6):703–713. doi:10.1046/j.1365-2265.1999.00695.x PMID: 10468912
  9. Regal M, Páramo C, Sierra JM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf). 2001;55(6):735–740. doi:10.1046/j.1365-2265.2001.01406.x PMID: 11895214
  10. Sherif IH, Vanderley CM, Beshyah S, Bosairi S. Sella size and contents in Sheehan's syndrome. Clin Endocrinol (Oxf). 1989;30(6):613–618. doi:10.1111/j.1365-2265.1989.tb00265.x PMID: 2590875